Veracyte Inc (OQ:VCYT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 6000 Shoreline Court, Suite 300
Tel: N/A
IR: See website
Key People
Marc A. Stapley
Chief Executive Officer, Director
Rebecca Chambers
Chief Financial Officer
Annie Mcguire
Chief Human Resource Officer, General Counsel
Phillip G. Febbo
Chief Scientific Officer, Chief Medical Officer
John Leite
Chief Commercial Officer - CLIA
Business Overview
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Financial Overview
For the three months ended 31 March 2024, Veracyte Inc revenues increased 17% to $96.8M. Net loss decreased 77% to $1.9M. Revenues reflect Testing revenue increase of 25% to $90.3M. Lower net loss reflects Selling and marketing decrease of 9% to $23.8M (expense), Intangible asset amortization decrease of 31% to $3.7M (expense), Interest income increase from $1.2M to $2.7M (income).
Employees: 815 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,724M as of Mar 31, 2024
Annual revenue (TTM): $375.47M as of Mar 31, 2024
EBITDA (TTM): $13.52M as of Mar 31, 2024
Net annual income (TTM): -$68.18M as of Mar 31, 2024
Free cash flow (TTM): $26.33M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 76,448,070 as of May 3, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.